reports
Compass Pathways Announces First Quarter 2024 Financial Results and Bu...
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD)Michael Gold to join Compass as Head of R&DCompass enters into additional commercial collaborations, including with Reliant Medical Group, part of Optum Care Cash position of $262.9 million at March 31, 2024 Conference call May 8 at 8:00 a...
AvidXchange Announces First Quarter 2024 Financial Results
AvidXchange Announces First Quarter 2024 Financial Results Strong across-the-board year-over-year Q1’24 financial performance driven by yield expansion, transaction growth, unit cost reduction and operating expense disciplineQ1’24 operating income loss of $(4.1) million more than halved versus a loss of $(17.1) million in the comparable year-ago periodQ1’24 adjusted EBITDA up sharply to $17.7 million vs. $0.4 million in the comparable year-ago periodSustaining a strong balance sheet with cash and marketable securities of $443.6 million to re-invest in the core business organically and inorg...
Brookfield Asset Management Announces Strong First Quarter Results
Brookfield Asset Management Announces Strong First Quarter Results Insurance Flows and Castlelake Add $75 Billion of AUM Since Quarter End $106 Billion of Dry Powder Available to Invest BROOKFIELD, NEWS, May 08, 2024 (GLOBE NEWSWIRE) -- Brookfield Asset Management Ltd. (NYSE: BAM, TSX: BAM) today announced financial results for the quarter ended March 31, 2024. Connor Teskey, President of Brookfield Asset Management stated, “We are off to a strong start in 2024 and are seeing accelerating momentum across our business as transaction activity picks up. We raised $20 billion of capital du...
Sandvik AB: 3 directors
Two Directors at Sandvik AB sold/bought 25,708 shares at between 225.100SEK and 226.360SEK. The significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
Ancom Nylex Berhad: 1 director
A director at Ancom Nylex Berhad bought 2,000,000 shares at 1.020MYR and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Rani Zim Shoping Centers Ltd: 1 director
A director at Rani Zim Shoping Centers Ltd sold 3,950,897 shares at 2.820ILS and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Ra...
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer of Cellectar, will present an overview of the company in a fireside chat at the upcoming Guggenheim Healthcare Talks Radiopharmaceuticals Day being held on May 13, 2024 in New York City. Details of...
Temenos Multifonds extends partnership with Citi Securities Services t...
Temenos Multifonds extends partnership with Citi Securities Services to consolidate global funds services on Multifonds SaaS Move to Multifonds SaaS enables Citi Securities Services to manage its global business efficiently on a single platform GENEVA, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Today, Temenos (SIX: TEMN) announced that Multifonds has extended its relationship with Citi Securities Services to consolidate its current regional fund accounting operation into a global operating model on delivered as SaaS. Citi Securities Services provides end-to-end services for asset m...
EQS-News: Immunic, Inc. Reports First Quarter 2024 Financial Results a...
Issuer: Immunic AG / Key word(s): Quarter Results/Quarterly / Interim Statement Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update 08.05.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update – Substantially Bolstered Balance Sheet Through a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche – – Received Fo...
Moody's Ratings changes Barry Callebaut's outlook to stable; affirms B...
Moody's Ratings (Moody's) has today affirmed Barry Callebaut AG's ("Barry Callebaut" or "the company") Baa3 long-term issuer rating and the Baa3 backed senior unsecured rating on the notes issued by Barry Callebaut Services N.V.. The outlook on both entities has been changed to stable from positive....
- Hiroyuki Terada
- Joel Scheiman
- Julie Boote
- Lindsay Whipp
- Pelham Smithers
- William Nestuk
PSA Today 8 May: Lower on weak earnings / Video Games round-up / Disap...
PSA Today Japan Market Comment by Pelham Smithers, Julie Boote, Joel Scheiman, William Nestuk, Lindsay Whipp and Hiroyuki Terada Tags: Ricoh (7752 JT), JFE (5411 JT), Nintendo (7974 JT), Mitsubishi Heavy Industries (7011 JT), Sumitomo Corp (8053 JT), Sony (6758 JT), Paramount (PARA US), Nintendo (7974 JT), Two Interactive (TTWO US), JMDC (4483 JT), Yokogawa Electric (6841 JT), AGC (5201 JT), Lintec (7966 JT), KH Neochem (4189 JT), Toray (3402 JT), Microsoft (MSFT US), Nintendo (7974 JT), Electr...
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOL...
PARSIPPANY, N.J. & TEL AVIV & PARIS--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), today announced results from the efficacy portion of the Phase 3 Subcutaneous OLAnzapine extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients with schizophrenia compared to placebo. Results demonstrated that TEV-‘749 met its primary endpoint as measured by a change in the PANSS total score from baseline after 8 weeks compared to placebo. TEV-‘749 utilizes SteadyTeq™, a co...
Compass Pathways announces durable improvement in symptoms through 12 ...
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5 point reduction at week 12), with change from baseline in mean SDS total score (14.4 point reduction at week 12)81.8% response (reduction of ≥ 15 points in CAPS-5 score), 63.6% remission (total CAPS-5 ≤ 20) rates at week 4 with 77.3% re...
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global He...
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the RBC Capital Markets 2024 Global Healthcare Conference on Wednesday, May 15, 2024, at 1:35 p.m. ET in New York City. A live webcast will be available in the investor section of the company's website at , and will be archived for 60 day...
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress...
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program --Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDs with significant relevant medical, clinical and scientific expertise-- --Company to present this month at upcoming American Association of Clinical Endocrinology annual meeting and GLP-1 Based Therapeutics Summit-- --Company to host confe...
Azimut and SOQUEM Cut Very High Grade Lithium Drill Intercepts on Gali...
Azimut and SOQUEM Cut Very High Grade Lithium Drill Intercepts on Galinée, James Bay Region, Quebec 2.68% Li2O over 54.6 m including 3.48% Li2O over 35.85 m LONGUEIL, Quebec, May 08, 2024 (GLOBE NEWSWIRE) -- Azimut Exploration Inc. (“Azimut” or the “Company”) (TSXV: AZM) (OTCQX: AZMTF) is pleased to report the first set of results from the second phase of diamond drilling on the Galinée Property (the “Property”) in the Eeyou Istchee James Bay region of Quebec, Canada. During this second phase, 14 holes were drilled for a total of 3,203.65 metres, including two extended holes ...
Azimut et SOQUEM recoupent par forage de très hautes teneurs en lithiu...
Azimut et SOQUEM recoupent par forage de très hautes teneurs en lithium sur Galinée, région de la Baie James, Québec 2,68% Li2O sur 54,6 m incluant 3,48% Li2O sur 35,85 m LONGUEIL, Québec, 08 mai 2024 (GLOBE NEWSWIRE) -- Exploration Azimut Inc. (« Azimut » ou la « Société ») (TSXV : AZM) (OTCQX : AZMTF) annonce les premiers résultats de la seconde phase de forage au diamant effectuée sur la Propriété Galinée (la « Propriété ») dans la région Eeyou Istchee Baie James au Québec, Canada. Au cours de cette seconde phase, 14 trous ont été forés pour un total de 3 203,65 m, incluant ...
Ducommun Incorporated Reports First Quarter 2024 Results
Ducommun Incorporated Reports First Quarter 2024 Results Record Start to the Year for both Q1 Revenue and Gross Margins SANTA ANA, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) today reported results for its first quarter ended March 30, 2024. First Quarter 2024 Recap Net revenue was $190.8 million, an increase of 5.3% over Q1 2023Net income of $6.8 million, or $0.46 per diluted share, or 3.6% of revenue, up 70 bps year-over-yearNon-GAAP adjusted net income of $10.4 million, or $0.70 per diluted sha...
Teva et Medincell annoncent des résultats d'efficacité positifs pour l...
PARSIPPANY, N.J. & TEL AVIV & PARIS--(BUSINESS WIRE)-- Regulatory News: Teva Pharmaceuticals, filiale américaine de Teva Pharmaceutical Industries Ltd. (NYSE et TASE : TEVA), et Medincell (Euronext : MEDCL), ont annoncé aujourd'hui les résultats de la partie efficacité de l’étude de phase 3 SOLARIS (Subcutaneous OLAnzapine extended-Release Injection Study) évaluant TV-‘749 chez des patients adultes atteints de schizophrénie, par rapport à un groupe placebo. Les résultats démontrent que TV-‘749 a atteint le critère d'évaluation principal de l’étude, mesuré par l’évolution du score total sur l...
Trane Technologies and the U.S. Department of Energy Partner to Advanc...
SWORDS, Ireland--(BUSINESS WIRE)-- Trane Technologies (NYSE: TT), a global climate innovator, today announced its participation in the . This new initiative is designed to advance the adoption of cost-effective, next-generation heat pump rooftop units and cut carbon emissions. Heat pump rooftop units can reduce greenhouse gas emissions and energy costs by up to 50% compared with conventional rooftop units using natural gas heating. Partnering with the DOE and its national laboratories to create prototypes, test product performance and durability and conduct field trials, Trane Technologies w...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.